Akèy › Lukemi lenfositè kwonik › Iowa › Des Moines
Etid klinik pou Lukemi lenfositè kwonik nan Des Moines, IA
8 etid pou Lukemi lenfositè kwonik ap chèche patisipan nan sit nan ak bò kote Des Moines (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Ap rekriteFaz 3
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Broadlawns Medical Center, Des Moines
- ak 5 plis
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Mercy Medical Center - Des Moines, Des Moines
- ak 6 plis
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Ap rekriteFaz 3
- Iowa Methodist Medical Center, Des Moines
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines
- Broadlawns Medical Center, Des Moines
- ak 5 plis
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Ap rekriteFaz 3
- Mission Cancer and Blood, Waukee · 14 mi lwen
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Ap rekriteFaz 3
- Mission Cancer and Blood, Waukee · 14 mi lwen
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Ap rekriteFaz 3
- University of Iowa Health Care. ( Site 0057), Waukee · 14 mi lwen
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ap rekriteFaz 2
- Mission Cancer + Blood, Waukee · 14 mi lwen
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Ap rekriteFaz 3
- University of Iowa Health Care /ID# 267206, Des Moines
Etid Lukemi lenfositè kwonik nan lòt vil
- Boston, MA31 etid
- Columbus, OH28 etid
- Durham, NC27 etid
- Washington, DC22 etid
- Seattle, WA20 etid
- Rochester, MN19 etid
- New York City, NY18 etid
- Houston, TX17 etid
- Baldwin Park, CA16 etid
- Milwaukee, WI15 etid
- Cincinnati, OH14 etid
- Chicago, IL14 etid
Lòt etid nan Des Moines
- Kansè Poumon ki pa ti selil11 etid
- Kansè poumon10 etid
- Kansè kolorektal8 etid
- Kansè nan tete8 etid
- Sipwa6 etid
- Kansè vejik6 etid
- Kansè pwostat5 etid
- Myelom Miltip5 etid
- Melanom5 etid
- Maladi kadyovaskilè5 etid
- Obèsite5 etid
- Dyabèt Tip 25 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.